Medium-term plans, capital spending, new plants, products and drug approvals from Japanese companies.
TRIAL Holdings ties its ¥64.0bn operating-profit target for the year to June 2029 to converting 30 Seiyu hypermarkets, a ¥13bn purchasing gain by mid-2027 and a ¥45bn private-label and category-management gain.
Taiyo Yuden and TDK signed a basic agreement to study joint development of MLCCs and inductors for AI hardware, with manufacturing, procurement, a possible METI application and any capital tie-up still to be discussed.
Shikoku Electric will raise all low-voltage plans from 1 November to pass on higher wheeling charges, with sample household bills up ¥478 to ¥777 a month and an earnings effect it expects to track the grid arm's ¥23.9bn annual gain.
Oki Electric Industry expects about ¥10bn in special retirement payments after 668 group employees applied for its second-career scheme, booked in the second quarter with the full-year consolidated forecast left unchanged.
Kansai Electric's modeled low-voltage bills rise 4.3% to 6.9% from 1 November as revised grid charges pass through, while sample high-voltage users on the current standard menu see 2.3% to 2.9% and extra-high-voltage examples 0.5%.
JX Advanced Metals and Tronox plan to fund half each of a $32mn study, targeted to finish in 2027, on whether a rare-earth refining business of up to about 10,000 tonnes a year is viable in Australia, the US or elsewhere.
Arisawa Mfg. has a grant decision capping its METI subsidy at ¥2.127bn for a roughly ¥14bn Gifu plant, but the payout depends on a post-completion inspection and comes with a 7.6% average annual pay-rise target.
AeroEdge, one of only two global suppliers of titanium-aluminide blades for Safran's LEAP jet engine, has locked in a market-share increase from 40% to the high-40s per cent range starting January 2028, tied to a new alloy it developed with Japan's materials-research institute.
Achilles Corporation's board has resolved to end production at its wholly owned vehicle-materials plant in Foshan, China, by the end of September, after three years of losses that included a ¥3.26bn impairment, citing the retreat of Japanese automakers from China among its reasons, though it expects only a minor effect on its earnings outlook for the year to March 2027.
An interim analysis of Chugai's Phase 2 obesity trial for the myostatin antibody emugrobart found the targeted weight loss unlikely, so Roche is exiting the program entirely and is set to return all license rights to Chugai, which is now preparing, but has not decided, a possible return to spinal muscular atrophy development.
Tohoku Electric will raise electricity rates for every customer class from November 1, adding ¥485 a month to a typical household bill and around ¥17,000 to an office or commercial building's, as its grid subsidiary's revised wheeling charges take effect the same day. The company expects the change to improve group earnings by roughly ¥30bn this fiscal year, but has not folded that into full-year guidance.
Japan's health ministry designated Renascience's RS5614 an orphan drug for the rare skin cancer cutaneous angiosarcoma, extending exclusivity and adding a pricing premium, while the company discusses a Phase 3 trial with Japan's PMDA aimed at regulatory approval.
Hokkaido Electric is raising regulated and liberalized electricity tariffs from November 1, lifting a standard household bill from ¥11,115 to ¥11,596 as it passes through a higher grid-usage fee set by the region's grid operator.
SymBio Pharmaceuticals has signed an exclusive global license with the US Department of Health and Human Services to develop brincidofovir against multiple sclerosis, but the programme remains in animal testing, and the company disclosed no financial terms while saying the deal will not affect its earnings forecast for the year ending December 2026.
The Osaka biotech's IND filing asks the FDA to clear a US Phase III trial of oremepermin alfa, its lab-made HGF protein already tested through Phase III in Japan for acute spinal cord injury, with the US study not yet started.
Datasection confirmed a customer paid $98.55 million of a required $131.4 million deposit, meeting the condition that made its previously announced large order contractually effective, with $32.85 million scheduled to be paid within 30 days and the customer's identity and commercial terms not named in the filing.
Quantum Solutions canceled its first AI data-center hardware contract days after paying $8.3 million upfront, after the supplier said supply constraints would push delivery out to about 36 weeks, and the refund is still working its way back to the company's account.
Yamaichi Electronics will spend about ¥6.5bn on a fourth Philippine factory, at roughly 30,000 square meters bigger than its existing three plants combined, to assemble semiconductor test sockets and connectors for AI-server, automotive and industrial demand it expects to grow, though the plant will not open until the second half of the fiscal year ending March 2029.
SEKI plans to invest roughly ¥4.3bn in a new water-based flexo printing plant in Toon City, Ehime Prefecture, adding food-pouch and beverage-label capacity that will not start operating until April 2028.
Terra Drone told investors it landed two Ministry of Defense tenders far faster than the usual three-to-four-year entry timeline and expects its first defense revenue in September or October, while betting that a mandatory domestic-parts rule for flight controllers, batteries, motors and chargers would strengthen its position against foreign suppliers.
Air Water is screening every subsidiary in its group on strategic fit, financial performance and governance, and says businesses judged better suited to a different owner will be transferred promptly, with proceeds funding both extra shareholder payouts and ongoing growth investment.
SanBio's newly launched cell therapy for chronic motor paralysis after traumatic brain injury, priced at ¥72.7mn a treatment, has generated no revenue and no dosed patients four months after its Japanese launch, and the company is now targeting only six cases by the fiscal year-end in January while its cash pile fell ¥2.34bn to ¥12.75bn over the same half-year.
A Japanese consortium ran a naphtha cracking furnace on 85% ammonia fuel by putting its main burners on 100% ammonia while flame-shaping burners stayed on methane off-gas, holding nitrogen-oxide emissions at existing levels, with full ammonia firing and commercial-scale trials still to come.
Shionogi cleared a Japanese approval adding a booster dose to its Omicron JN.1 COVID-19 vaccine, completing the technical groundwork for supplying future season-matched shots, but the approved formulation itself won't be sold because it doesn't match the strain designated for the 2026-2027 season.